单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识

doi:10.3969/j.issn.1673-5765.2026.01.010

中国卒中杂志 ›› 2026, Vol. 21 ›› Issue (1): 88-98.DOI: 10.3969/j.issn.1673-5765.2026.01.010

单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识

中国卒中学会，《单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识》专家组

广州 510632 暨南大学临床神经科学研究所，暨南大学附属第一医院神经内科（徐安定）
杭州 310000 浙江大学医学院附属第一医院（罗本燕）
南京 210000 南京大学医学院附属鼓楼医院（徐运）

收稿日期:2025-11-07 修回日期:2025-12-15 接受日期:2025-12-30 出版日期:2026-01-20 发布日期:2026-01-20
通讯作者: 徐安定 tlil@jnu.edu.cn 罗本燕 luobenyan@zju.edu.cn 徐运 xuyun20042001@aliyun.com

Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke

Chinese Stroke Association, Writing Group of Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke

Clinical Neuroscience Institute of Jinan University, Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou 510632, China (XU Anding) The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China (LUO Benyan) Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210000, China (XU Yun)

Received:2025-11-07 Revised:2025-12-15 Accepted:2025-12-30 Online:2026-01-20 Published:2026-01-20
Contact: XU Anding, E-mail: tlil@jnu.edu.cn LUO Benyan, E-mail: luobenyan@zju.edu.cn XU Yun, E-mail: xuyun20042001@aliyun.com

摘要/Abstract

摘要： 为进一步规范单唾液酸四己糖神经节苷脂（monosialotetrahexosylganglioside，GM1）在急性缺血性卒中临床治疗中的应用，保障其用药安全并优化疗效，中国卒中学会成立专家组，在系统梳理国内外最新临床研究证据的基础上，结合专家临床实践经验，通过多次讨论与修改，最终制定了《单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识》。本共识系统阐述了GM1的药理机制，聚焦GM1治疗急性缺血性卒中的4个核心临床问题：有效性和用药时机、安全性和常见不良反应、联合再灌注治疗的疗效，以及在特殊急性缺血性卒中患者中的应用，并就此形成了可行性共识建议。本共识的制订旨在为我国临床医师规范应用GM1治疗急性缺血性卒中提供科学参考与指导。

关键词: 单唾液酸四己糖神经节苷脂; 急性缺血性卒中; 专家共识

Abstract: To further standardize the application of monosialotetrahexosylganglioside (GM1) in the treatment of acute ischemic stroke (AIS), ensure medication safety, and optimize therapeutic efficacy, the Chinese Stroke Association convened a panel of experts. Based on a systematic review of the latest clinical research evidence from both domestic and international studies, and incorporating experts’ clinical expertise, the panel developed the Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke through multiple rounds of discussion and revision. This consensus systematically elaborates on the pharmacological mechanisms of GM1, focusing on four key clinical issues: the efficacy and timing of GM1 in the treatment of AIS, its safety and common adverse reactions, its effectiveness in combination with reperfusion therapy, and its application in special AIS populations. Targeted and feasible consensus recommendations have been formed accordingly. The development of this consensus aims to provide scientific reference and guidance for clinicians in China to standardize the use of GM1 in the treatment of AIS.

Key words: Monosialotetrahexosylganglioside; Acute ischemic stroke; Expert consensus

中图分类号:

中国卒中学会, 《单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识》专家组. 单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识[J]. 中国卒中杂志, 2026, 21(1): 88-98.

Chinese Stroke Association, Writing Group of Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke. Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2026, 21(1): 88-98.

参考文献

[1] MA Q F，LI R，WANG L J，et al. Temporal trend and attributable risk factors of stroke burden in China，1990-2019：an analysis for the global burden of disease study 2019[J/OL]. Lancet Public Health，2021，6（12）：e897-e906[2025-10-30]. https://doi.org/10.1016/s2468-2667(21)00228-0.
[2] TU W J，WANG L D，Special Writing Group of China Stroke Surveillance Report. China stroke surveillance report 2021[J/OL]. Mil Med Res，2023，10：33[2025-10-30]. https://doi.org/10.1186/s40779-023-00463-x.
[3] 中国老年医学学会脑血管病分会. 缺血性卒中脑细胞保护临床实践中国专家共识[J]. 国际神经病学神经外科学杂志，2025，52（2）：1-7.
Cerebrovascular Diseases Branch，Chinese Geriatrics Society. Chinese expert consensus on clinical practice for brain cytoprotection in ischemic stroke[J]. Journal of International Neurology and Neurosurgery，2025，52（2）：1-7.
[4] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组. 中国急性缺血性卒中诊治指南2023[J]. 中华神经科杂志，2024，57（6）：523-559.
Chinese Society of Neurology，Chinese Stroke Society. Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2023[J]. Chin J Neurol，2024，57（6）：523-559.
[5] 逯丹，陈玮琪，王雅平，等. 缺血性卒中脑细胞保护科学声明——来自中国卒中学会的科学声明[J]. 中国卒中杂志，2024，19（8）：938-955.
LU D，CHEN W Q，WANG Y P，et al. Scientific statement on brain cytoprotection in ischemic stroke—a scientific statement from the Chinese Stroke Association[J]. Chin J Stroke，2024，19（8）：938-955.
[6] GUO Z W. Ganglioside GM1 and the central nervous system[J/OL]. Int J Mol Sci，2023，24（11）：9558[2025-10-30]. https://doi.org/10.3390/ijms24119558.
[7] ZHANG W C，KRAFFT P R，WANG T L，et al. Pathophysiology of ganglioside GM1 in ischemic stroke：ganglioside GM1：a critical review[J]. Cell Transplant，2019，28（6）：657-661.
[8] AURELI M，MAURI L，CIAMPA M G，et al. GM1 ganglioside：past studies and future potential[J]. Mol Neurobiol，2016，53（3）：1824-1842.
[9] 中华医学会创伤学分会神经损伤专业组. 单唾液酸四己糖神经节苷脂钠盐注射液——治疗脑、脊髓损伤患者的专家共识[J]. 中华创伤杂志，2010，26（1）：6-8.
Neurotrauma Group of Chinese Society of Traumatology. Expert consensus on monosialotetrahexosylganglioside sodium injection for the treatment of patients with brain and spinal cord injuries[J]. Chinese Journal of Trauma，2010，26（1）：6-8.
[10] 赛典单唾液酸四己糖神经节苷脂钠注射液[EB/OL].（2024-10-18）[2025-03-17]. https://www.ssyy.com.cn/product/31.html.
[11] ZHANG X，XU Y，GUO A，et al. The randomized，double-blind，placebo-controlled，phase 3 FOCUS study of ganglioside GM1 for acute ischemic stroke（AIS）[J/OL]. Int J Stroke, 2025（2_suppl）：4[2025-11-12]. https://pubmed.ncbi.nlm.nih.gov/41287587/.
[12] SCHNAAR R L. The biology of gangliosides[J/OL]. Adv Carbohydr Chem Biochem，2019，76：113-148[2025-10-30]. https://doi.org/10.1016/bs.accb.2018.09.002.
[13] NOBILE-ORAZIO E，CARPO M，SCARLATO G. Gangliosides. Their role in clinical neurology[J]. Drugs，1994，47（4）：576-585.
[14] MOCCHETTI I. Exogenous gangliosides，neuronal plasticity and repair，and the neurotrophins[J]. Cell Mol Life Sci，2005，62（19/20）：2283-2294.
[15] ZHANG J，FANG X，ZHOU Y Y，et al. The possible damaged mechanism and the preventive effect of monosialotetrahexosylganglioside in a rat model of cerebral ischemia-reperfusion injury[J]. J Stroke Cerebrovasc Dis，2015，24（7）：1471-1478.
[16] LIU J R，DING M P，WEI E Q，et al. GM1 stabilizes expression of NMDA receptor subunit 1 in the ischemic hemisphere of MCAo/reperfusion rat[J]. J Zhejiang Univ Sci B，2005，6（4）：254-258.
[17] GONG G，YIN L，YUAN L B，et al. Ganglioside GM1 protects against high altitude cerebral edema in rats by suppressing the oxidative stress and inflammatory response via the PI3K/AKT-Nrf2 pathway[J/OL]. Mol Immunol，2018，95：91-98[2025-10-30]. https://doi.org/10.1016/j.molimm.2018.02.001.
[18] SHI Y W，XU C C，SUN C Y，et al. GM1 ameliorates neuronal injury in rats after cerebral ischemia and reperfusion：potential contribution of effects on SPTBN1-mediated signaling[J/OL]. Neuroscience，2024，551：103-118[2025-10-30]. https://doi.org/10.1016/j.neuroscience.2024.05.031.
[19] GALLEGUILLOS D，WANG Q，STEINBERG N，et al. Anti-inflammatory role of GM1 and other gangliosides on microglia[J/OL]. J Neuroinflammation，2022，19：9[2025-10-30]. https://doi.org/10.1186/s12974-021-02374-x.
[20] MAHADIK S P，HUNGUND B L，GOKHALE V S，et al. Monosialoganglioside（GM1）restores membrane fatty acid levels in ischemic tissue after cortical focal ischemia in rat[J]. Neurochem Int，1993，23（2）：163-172.
[21] MAHADIK S P，HAWVER D B，HUNGUND B L，et al. GM1 ganglioside treatment after global ischemia protects changes in membrane fatty acids and properties of Na+，K+-ATPase and Mg2+-ATPase[J]. J Neurosci Res，1989，24（3）：402-412.
[22] MAHADIK S P，BHARUCHA V A，STADLIN A，et al. Loss and recovery of activities of α+ and α isozymes of（Na++K+）-ATPase in cortical focal ischemia：GM1 ganglioside protects plasma membrane structure and function[J]. J Neurosci Res，1992，32（2）：209-220.
[23] SIPIONE S，MONYROR J，GALLEGUILLOS D，et al. Gangliosides in the brain：physiology，pathophysiology and therapeutic applications[J/OL]. Front Neurosci，2020，14：572965[2025-10-30]. https://doi.org/10.3389/fnins.2020.572965.
[24] LI L，TIAN J H，LONG M K W，et al. Protection against experimental stroke by ganglioside GM1 is associated with the inhibition of autophagy[J/OL]. PLoS One，2016，11（1）：e0144219[2025-10-30]. https://doi.org/10.1371/journal.pone.0144219.
[25] CHIRICOZZI E，LUNGHI G，DI BIASE E，et al. GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration[J/OL]. Int J Mol Sci，2020，21（3）：868[2025-10-30]. https://doi.org/10.3390/ijms21030868.
[26] LENZI G L，GRIGOLETTO F，GENT M，et al. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the early stroke trial[J]. Stroke，1994，25（8）：1552-1558.
[27] The SASS Investigators. Ganglioside GM1 in acute ischemic stroke. The SASS trial[J]. Stroke，1994，25（6）：1141-1148.
[28] ARGENTINO C，SACCHETTI M L，TONI D，et al. GM1 ganglioside therapy in acute ischemic stroke. For the Italian acute stroke study—hemodilution+drug[J]. Stroke，1989，20（9）：1143-1149.
[29] 曾保起，周庆欣，高乐，等. 单唾液酸四己糖神经节苷脂治疗急性缺血性脑卒中的系统综述与meta分析[J]. 中国新药杂志，2020，29（1）：105-112.
ZENG B Q，ZHOU Q X，GAO L，et al. GM1 ganglioside therapy in acute ischemic stroke：a systematic review and meta-analysis[J]. Chinese Journal of New Drugs，2020，29（1）：105-112.
[30] CANDELISE L，CICCONE A. Gangliosides for acute ischaemic stroke[J/OL]. Cochrane Database Syst Rev，2001（4）：CD000094[2025-10-30]. https://doi.org/10.1002/14651858.CD000094.
[31] 王凯，杨珍珍，韩晟，等. 单唾液酸四己糖神经节苷脂治疗急性脑梗死的有效性与安全性的meta分析[J]. 中国新药杂志，2018，27（20）：2458-2464.
WANG K，YANG Z Z，HAN S，et al. Meta-analysis of the efficacy and safety of monosialotetrahexosyl ganglioside on acute ischemic stroke[J]. Chinese Journal of New Drugs，2018，27（20）：2458-2464.
[32] SCHWERER B，PICHLER S，BERNHEIMER H，et al. Chronic progressive motor polyneuropathy after ganglioside treatment[J/OL]. J Neurol Neurosurg Psychiatry，1994，57（2）：238[2025-10-30]. https://doi.org/10.1136/jnnp.57.2.238.
[33] ODAKA M，YUKI N，NOBILE-ORAZIO E，et al. Antibodies to GM1（NeuGc）in Guillain-Barré syndrome after ganglioside therapy[J]. J Neurol Sci，2000，175（2）：96-106.
[34] LANDI G，D’ALESSANDRO R，DOSSI B C，et al. Guillain-Barré syndrome after exogenous gangliosides in Italy[J]. BMJ，1993，307（6917）：1463-1464.
[35] GOVONI V，GRANIERI E，TOLA M R，et al. Exogenous gangliosides and Guillain-Barré syndrome. An observational study in the local health district of Ferrara，Italy[J]. Brain，1997，120（Pt 7）：1123-1130.
[36] MAGISTRETTI P J，GEISLER F H，SCHNEIDER J S，et al. Gangliosides：treatment avenues in neurodegenerative disease[J/OL]. Front Neurol，2019，10：859[2025-10-30]. https://doi.org/10.3389/fneur.2019.00859.
[37] 陈玥，李佳安，朱曼，等. 神经节苷脂致吉兰巴雷综合征的文献分析[J]. 临床药物治疗杂志，2020，18（9）：53-57.
CHEN Y，LI J A，ZHU M，et al. Literature analysis of gangliosides induced Guillain-Barre syndrome[J]. Clinical Medication Journal，2020，18（9）：53-57.
[38] WU X J，WU W，WANG Z Z，et al. More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in Northeast China[J/OL]. PLoS One，2014，9（8）：e104074[2025-10-30]. https://doi.org/10.1371/journal.pone.0104074.
[39] SHI M，ZHU J，DENG H. Clinical characteristics of intravenous injection of monosialotetrahexosyl ganglioside sodium-related Guillain-Barré syndrome[J/OL]. Front Neurol，2019，10：225[2025-10-30]. https://doi.org/10.3389/fneur.2019.00225.
[40] ILLA I，ORTIZ N，GALLARD E，et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides[J]. Ann Neurol，1995，38（2）：218-224.
[41] GOVONI V，GRANIERI E，MANCONI M，et al. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy？A population-based study in the local health district of Ferrara，Italy[J]. J Neurol Sci，2003，216（1）：99-103.
[42] 中华医学会神经病学分会，中华医学会神经病学分会周围神经病协作组. 中国吉兰-巴雷综合征诊治指南2024[J]. 中华神经科杂志，2024，57（9）：936-944. .
Chinese Society of Neurology，Peripheral Neuropathy Collaboration Group of Chinese Society of Neurology. Chinese guideline on diagnosis and treatment of Guillain-Barré syndrome 2024[J]. Chin J Neurol，2024，57（9）：936-944.
[43] 姚东陂，张锦丽，单志刚，等. 静脉溶栓联合单唾液酸四己糖神经节苷脂治疗脑梗死的疗效观察[J]. 中国医刊，2014，49（1）：47-48.
YAO D P，ZHANG J L，SHAN Z G，et al. Efficacy observation of intravenous thrombolysis combined with monosialotetrahexosylganglioside in the treatment of cerebral infarction[J]. Chinese Journal of Medicine，2014，49（1）：47-48.
[44] NICOLI E R，ANNUNZIATA I，D’AZZO A，et al. GM1 gangliosidosis—a mini-review[J/OL]. Front Genet，2021，12：734878[2025-10-30]. https://doi.org/10.3389/fgene.2021.734878.
[45] 白凤芝，李桂芳，于倩，等. 单唾液酸四己糖神经节苷脂钠注射液致严重过敏反应1例[J]. 中国实验诊断学，2015，19（9）：1584-1585.
BAI F Z，LI G F，YU Q，et al. Severe allergic reaction induced by monosialotetrahexosylganglioside sodium injection：a case report[J]. Chin J Lab Diagn，2015，19（9）：1584-1585.
[46] 王秀玲，宋伟，蔡其明. 单唾液酸四己糖神经节苷脂钠注射液致新的/严重的不良反应分析[J]. 解放军药学学报，2017，33（3）：282-284.
WANG X L，SONG W，CAI Q M. Analysis of new/severe adverse drug reactions caused by single sialic acid four hexose ganglioside sodium injections[J]. Pharmaceutical Journal of Chinese People’s Liberation Army，2017，33（3）：282-284.
[47] 黄雪梅，吴伟，李琴，等. 我院单唾液酸四己糖神经节苷脂钠注射液的临床应用监测研究[J]. 中国药房，2017，28（29）：4085-4089.
HUANG X M，WU W，LI Q，et al. Study on clinical application monitoring of monosialotetrahexosylganglioside sodium injection in our hospital[J]. China Pharmacy，2017，28（29）：4085-4089.
[48] SCHNEIDER J S，ROELTGEN D P，MANCALL E L，et al. Parkinson’s disease：improved function with GM1 ganglioside treatment in a randomized placebo-controlled study[J]. Neurology，1998，50（6）：1630-1636.
[49] SCHNEIDER J S，SENDEK S，DASKALAKIS C，et al. GM1 ganglioside in Parkinson’s disease：results of a five year open study[J]. J Neurol Sci，2010，292（1/2）：45-51.
[50] SCHNEIDER J S，GOLLOMP S M，SENDEK S，et al. A randomized，controlled，delayed start trial of GM1 ganglioside in treated Parkinson’s disease patients[J]. J Neurol Sci，2013，324（1/2）：140-148.
[51] ZHOU L K，LIU R，HUANG D Z，et al. Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity：TJMUCH-GI-001，a randomised controlled trial[J/OL]. eClinicalMedicine，2021，41：101157[2025-10-30]. https://doi.org/10.1016/j.eclinm.2021.101157.
[52] WANG D S，WANG Z Q，CHEN G，et al. Phase Ⅲ randomized，placebo-controlled，double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage Ⅱ/Ⅲ colorectal cancer[J]. Cancer Med，2020，9（1）：151-159.
[53] ZHU Y Y，YANG J L，JIAO S C，et al. Ganglioside-monosialic acid（GM1）prevents oxaliplatin-induced peripheral neurotoxicity in patients with gastrointestinal tumors[J/OL]. World J Surg Oncol，2013，11：19[2025-10-30]. https://doi.org/10.1186/1477-7819-11-19.
[54] SU Y H，HUANG J J，WANG S S，et al. The effects of ganglioside-monosialic acid in taxane-induced peripheral neurotoxicity in patients with breast cancer：a randomized trial[J]. J Natl Cancer Inst，2020，112（1）：55-62.
[55] XU J N，WANG Y，JIANG C，et al. Ganglioside monosialic acid alleviates peripheral neuropathy induced by utidelone plus capecitabine in metastatic breast cancer from a phase Ⅲ clinical trial[J/OL]. Front Oncol，2020，10：524223[2025-10-30]. https://doi.org/10.3389/fonc.2020.524223.
[56] PAPO I，BENEDETTI A，CARTERI A，et al. Monosialoganglioside in subarachnoid hemorrhage[J]. Stroke，1991，22（1）：22-26.
[57] CHEN Y K，TIAN H Y，ZHU Q Y，et al. Potential disease-modifying effects of ganglioside GM1 pulse treatment on spinocerebellar ataxia type 3，a parallel-group，double-blind，randomized，controlled trial[J]. Mov Disord，2025，40（1）：57-66.

单唾液酸四己糖神经节苷脂治疗急性缺血性卒中临床应用中国专家共识

Chinese Expert Consensus on the Clinical Application of Monosialotetrahexosylganglioside in Acute Ischemic Stroke

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	何丹丹, 许淑红, 李姝雅. 急性缺血性卒中标准时间窗内新型静脉溶栓药物临床研究及展望[J]. 中国卒中杂志, 2026, 21(1): 24-29.
[2]	黄旭阳, 李润辉. 替奈普酶与阿替普酶治疗急性缺血性卒中短期神经功能恢复比较：线性混合效应模型分析[J]. 中国卒中杂志, 2026, 21(1): 31-37.
[3]	何丹丹, 冯宝玉, 刘改芬, 谷鸿秋, 李姝雅. 中性粒细胞与淋巴细胞比值对急性缺血性卒中静脉溶栓患者预后的预测价值：基于3项随机对照试验的个体患者数据分析[J]. 中国卒中杂志, 2026, 21(1): 38-47.
[4]	赵敏, 冯宝玉, 何丹丹, 王维聪, 李姝雅. 瑞替普酶与阿替普酶治疗急性缺血性卒中合并心律失常患者的有效性及安全性比较[J]. 中国卒中杂志, 2026, 21(1): 48-54.
[5]	何丹丹, 李姝雅. 急性缺血性卒中静脉溶栓中外周血炎症指标与预后的研究进展[J]. 中国卒中杂志, 2026, 21(1): 55-64.
[6]	殷子欣, 鲁珊珊, 施海彬, 吴飞云, 许晓泉. 不同期相CTA脑静脉引流对急性缺血性卒中患者血管内治疗后短期预后的预测价值[J]. 中国卒中杂志, 2026, 21(1): 70-77.
[7]	班淇琦, 王苇, 郭远, 厉阳, 苏星月, 瞿航. 构建目标检测模型在NCCT上检测急性小面积梗死灶的研究[J]. 中国卒中杂志, 2026, 21(1): 78-87.
[8]	李欢, 于向明. 急性缺血性卒中DWI-FLAIR不匹配影像学判读研究进展[J]. 中国卒中杂志, 2025, 20(9): 1198-1202.
[9]	刘安利, 薛茜, 杨金水, 苗瑞瑞, 王欢欢. 抽吸取栓与支架取栓治疗急性缺血性卒中有效性及安全性的meta分析[J]. 中国卒中杂志, 2025, 20(8): 992-1005.
[10]	李子恒, 刘毅. 急性缺血性卒中静脉溶栓后早期抗血小板治疗的研究现状与展望[J]. 中国卒中杂志, 2025, 20(8): 1042-1050.
[11]	熊俞婷, 程爱春, 尹金风, 李子孝, 王春娟, 张静. BMI与急性缺血性卒中静脉溶栓患者院内结局的关系——基于中国卒中中心联盟登记数据库的分析[J]. 中国卒中杂志, 2025, 20(8): 1066-1072.
[12]	杨志进, 谭荃丹, 毛凤凯, 李朝晖, 陈晨, 李刚, 杨杰, 林亚鹏. 急性缺血性卒中超早期血压管理研究进展[J]. 中国卒中杂志, 2025, 20(7): 829-839.
[13]	中国中西医结合学会神经科专业委员会. 注射用丹参多酚酸治疗脑梗死临床应用中国专家共识[J]. 中国卒中杂志, 2025, 20(7): 878-898.
[14]	胡燕琴, 王铄, 赵陶丽, 郭东兴, 李申, 金振波. 丁苯酞序贯治疗急性缺血性卒中有效性和安全性的meta分析[J]. 中国卒中杂志, 2025, 20(6): 753-761.
[15]	董漪, 董强. 中国卒中临床研究中的溶栓治疗：20年的成就与发展方向[J]. 中国卒中杂志, 2025, 20(5): 549-554.